En sociedad

Informes de transparencia


Throughout Europe, the pharmaceutical sector is committed to disclosing payments or Transfers of Value to Healthcare Professionals and Healthcare Organizations by adopting the EFPIA Transparency Code. This code has been adopted by the local associations of the pharmaceutical industry for its implementation as Farmaindustria in the case of Spain.

The initiative responds to a voluntary commitment of the pharmaceutical companies that have signed the Code of Good Practices to make their relationships with Healthcare Organizations and Healthcare Professionals transparent, as well as the collaborations with Patient Organizations, making public the transfers of value derived from this interrelation . Laboratorios Galderma SA follows the principle of transparency and complies with the Code of Good Practices of the Pharmaceutical Industry of Farmaindustria and will publish on an annual basis the Transfers of Value that it has carried out during the calendar year derived from donations, training activities and scientific meetings. -professionals, provision of services and R&D with Healthcare Professionals and Healthcare Organizations. Laboratories Galderma S.A.

LABORATORIOS GALDERMA, SA has not collaborated with Patient Organizations in the 2021 financial year

-To see the report of the Transfers of Value carried out by Laboratorios Galderma SA in 2019 , click here .

-To see the report on the Transfers of Value carried out by Laboratorios Galderma SA in 2020 , click here .

-To see the report on the Transfers of Value carried out by Laboratorios Galderma SA in 2021 , click here .

-To see the explanatory Methodological Note on the transparency publication of Laboratorios Galderma, SA in 2021 , click here .

Para obtener más información sobre el código de buenas prácticas de la Industria Farmacéutica de Farmaindustria haga clic aquí; y para obtener más información sobre el código de transparencia de la EFPIA haga clic aquí.

La publicación de estos datos responde a las obligaciones de transparencia derivadas del Código de Buenas Prácticas de la Industria Farmacéutica. De la publicación de la información no se deriva una habilitación general para quienes accedan al sitio web puedan llevar a cabo un tratamiento adicional de los datos de los profesionales, tales como su cruce con las informaciones publicadas en los sitios web de otros asociados. El laboratorio ha adoptado niveles de seguridad para evitar la indexación de la información a través de motores de búsqueda.

C/ Serrano Galvache 56,
Parque Norte Business Center
Abedul Building, 5th floor
CP 28033 – Madrid (Spain)
Tel: +34 902 02 7595
Fax: +34 902 02 7595
Mail: Info.spain@galderma.com
To notify an adverse effect: Farmacovigilancia.spain@galderma.com